Humacyte (NASDAQ:HUMA) Upgraded to “Sell” at Wall Street Zen

Wall Street Zen upgraded shares of Humacyte (NASDAQ:HUMA) from a strong sell rating to a sell rating in a research report report published on Saturday morning.

Several other analysts have also recently weighed in on the company. Benchmark boosted their price target on Humacyte to $2.00 and gave the stock a “speculative buy” rating in a report on Monday, June 1st. TD Cowen dropped their price objective on shares of Humacyte from $1.50 to $1.25 and set a “buy” rating for the company in a report on Wednesday, June 17th. HC Wainwright lifted their target price on shares of Humacyte from $3.00 to $4.00 and gave the stock a “buy” rating in a research report on Thursday, June 11th. BTIG Research reissued a “buy” rating and set a $2.00 target price on shares of Humacyte in a report on Tuesday, July 28th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Humacyte in a research report on Wednesday, July 8th. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $6.25.

Humacyte Stock Down 2.7%

Shares of HUMA opened at $0.65 on Friday. The company has a debt-to-equity ratio of 5.46, a quick ratio of 3.32 and a current ratio of 3.93. Humacyte has a 52 week low of $0.55 and a 52 week high of $2.76. The stock has a market capitalization of $145.07 million, a price-to-earnings ratio of -1.15 and a beta of 2.52. The stock has a fifty day moving average of $0.90 and a 200-day moving average of $0.93.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01. Humacyte had a negative return on equity of 2,914.18% and a negative net margin of 4,836.06%.The business had revenue of $0.49 million for the quarter, compared to analyst estimates of $1.46 million. As a group, sell-side analysts anticipate that Humacyte will post -0.34 earnings per share for the current fiscal year.

Insider Transactions at Humacyte

In other Humacyte news, CFO Dale A. Sander sold 45,887 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $0.90, for a total value of $41,298.30. Following the completion of the sale, the chief financial officer owned 267,213 shares of the company’s stock, valued at approximately $240,491.70. This trade represents a 14.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Shamik J. Parikh sold 45,887 shares of the business’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $0.90, for a total transaction of $41,298.30. Following the sale, the insider owned 272,713 shares of the company’s stock, valued at $245,441.70. This trade represents a 14.40% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 3.10% of the company’s stock.

Institutional Trading of Humacyte

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. UBS Group AG lifted its holdings in shares of Humacyte by 48.8% in the fourth quarter. UBS Group AG now owns 2,978,610 shares of the company’s stock valued at $2,862,000 after purchasing an additional 976,275 shares in the last quarter. R Squared Ltd purchased a new stake in Humacyte in the 4th quarter valued at $25,000. United Asset Strategies Inc. lifted its stake in Humacyte by 13.5% during the 4th quarter. United Asset Strategies Inc. now owns 209,608 shares of the company’s stock valued at $201,000 after acquiring an additional 25,000 shares in the last quarter. SG Americas Securities LLC boosted its holdings in Humacyte by 50.3% during the 4th quarter. SG Americas Securities LLC now owns 34,075 shares of the company’s stock worth $33,000 after acquiring an additional 11,411 shares during the last quarter. Finally, Prudential Financial Inc. bought a new stake in shares of Humacyte in the 2nd quarter worth $28,000. 44.71% of the stock is owned by institutional investors.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.